Leni and Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai, New York, NY,
Eur Cell Mater. 2020 Nov 18;40:239-258. doi: 10.22203/eCM.v040a15.
Discogenic back pain is a common condition without approved intervertebral disc (IVD) repair therapies. Cell delivery using injectable biomaterial carriers offers promise to restore disc height and biomechanical function, while providing a functional niche for delivered cells to repair degenerated tissues. This systematic review advances the injectable IVD cell delivery biomaterials field by characterising its current state and identifying themes of promising strategies. Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA) guidelines were used to screen the literature and 183 manuscripts met the inclusion criteria. Cellular and biomaterial inputs, and biological and biomechanical outcomes were extracted from each study. Most identified studies targeted nucleus pulposus (NP) repair. No consensus exists on cell type or biomaterial carrier, yet most common strategies used mesenchymal stem cell (MSC) delivery with interpenetrating network/co-polymeric (IPN/CoP) biomaterials composed of natural biomaterials. All studies reported biological outcomes with about half the studies reporting biomechanical outcomes. Since the IVD is a load-bearing tissue, studies reporting compressive and shear moduli were analysed and two major themes were found. First, a competitive balance, or 'seesaw' effect, between biomechanical and biological performance was observed. Formulations with higher moduli had inferior cellular performance, and vice versa. Second, several low-modulus biomaterials had favourable biological performance and matured throughout culture duration with enhanced extracellular matrix synthesis and biomechanical moduli. Findings identify an opportunity to develop next-generation biomaterials that provide high initial biomechanical competence to stabilise and repair damaged IVDs with a capacity to promote cell function for long-term healing.
椎间盘源性腰痛是一种常见病症,目前尚无经批准的治疗方法。采用可注射生物材料载体输送细胞,有望恢复椎间盘高度和生物力学功能,同时为输送细胞提供修复退变组织的功能小生境。本系统综述通过描述其现状并确定有前途的策略主题,推进了可注射椎间盘细胞输送生物材料领域。采用系统评价和荟萃分析的首选报告项目(PRISMA)指南筛选文献,有 183 篇符合纳入标准。从每项研究中提取细胞和生物材料输入以及生物和生物力学结果。大多数确定的研究针对髓核修复。对于细胞类型或生物材料载体尚未达成共识,但最常见的策略是使用间充质干细胞(MSC)与由天然生物材料组成的互穿网络/共聚物(IPN/CoP)生物材料输送。所有研究均报告了生物学结果,约有一半的研究报告了生物力学结果。由于椎间盘是承重组织,因此分析了报告压缩和剪切模量的研究,并发现了两个主要主题。首先,观察到生物力学和生物学性能之间存在竞争平衡或“跷跷板”效应。具有较高模量的配方具有较差的细胞性能,反之亦然。其次,几种低模量生物材料具有良好的生物学性能,并在整个培养过程中成熟,细胞外基质合成和生物力学模量增加。研究结果表明,有机会开发下一代生物材料,这些材料具有高初始生物力学性能,能够稳定和修复受损的椎间盘,并具有促进长期愈合的细胞功能的能力。